

# References

## Chapter 36

- 1 World Health Organization. *Adherence to Long-Term Therapies: Evidence for Action*. Geneva, World Health Organization, 2003.
- 2 Wahl C, Gregoire JP, Teo K, Beaulieu M, Labelle S, Leduc B, et al. Concordance, compliance and adherence in healthcare: closing gaps and improving outcomes. *Healthcare Quality*. 2005;**8**(1):65–70.
- 3 Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppert T, et al. A new taxonomy for describing and defining adherence to medications. *British Journal of Clinical Pharmacology*. 2012;**73**(5):691–705.
- 4 Acri T, Gross R. Studies of medication adherence. In: Strom BL, Hennessy S, eds. *Pharmacoepidemiology*. Philadelphia, PA, John Wiley & Sons, 2012: 795–809.
- 5 Ogdie A, Langan SM, Parkinson J, Dattani H, Kostev K, Gelfand JM. Medical record databases. In: Strom BL, Hennessy S, eds. *Pharmacoepidemiology*. Philadelphia, PA, John Wiley & Sons, 2012: 224–43.
- 6 Begg D. Do patients cash prescriptions? An audit in one practice. *Journal of the Royal College of General Practitioners*. 1984;**34**(262):272–4.
- 7 Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. *British Medical Journal*. 1993;**307**(6908):846–8.
- 8 Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA, Weissman JS. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. *Journal of General Internal Medicine*. 2010;**25**(4):284–90.
- 9 Raebel MA, Ellis JL, Carroll NM, Bayliss EA, McGinnis B, Schroeder EB, et al. Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. *Journal of General Internal Medicine*. 2012;**27**(1):57–64.
- 10 Friedman DS, Hahn SR, Gelb L, Tan J, Shah SN, Kim EE, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. *Ophthalmology*. 2008;**115**(8):1320–7, e1–3.
- 11 Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. *British Medical Journal*. 1995;**311**(7000):293–5.
- 12 Li P, McElligott S, Bergquist H, Schwartz JS, Doshi JA. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia. *Annals of Internal Medicine*. 2012;**156**(11):776–84, W-263–W-269.
- 13 Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire JP. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. *Journal of Human Hypertension*. 2005;**19**(8):607–13.
- 14 Brookhart MA, Patrick AR, Schneeweiss S, Avorn J, Dormuth C, Shrank W, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. *Archives of Internal Medicine*. 2007;**167**(8):847–52.
- 15 Gregoire JP, Sirois C, Blanc G, Poirier P, Moisan J. Persistence patterns with oral antidiabetes drug treatment in newly treated patients – a population-based study. *Value Health*. 2010;**13**(6):820–8.
- 16 Geers HC, Bouvy ML, Heerdink ER. Estimates of statin discontinuation rates are influenced by exposure and outcome definitions. *Annals of Pharmacotherapy*. 2011;**45**(5):576–81.

- 17 Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. *Clinical Therapeutics*. 1998;**20**(4):671–81.
- 18 Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *New England Journal of Medicine*. 2005;**353**(12):1209–23.
- 19 Qvarnstrom M, Kahan T, Kieler H, Brandt L, Hasselstrom J, Bengtsson Bostrom K, et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. *European Journal of Clinical Pharmacology*. 2013;**69**(11):1955–64.
- 20 Cooper D, Moisan J, Gregoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. *Journal of Clinical Psychiatry*. 2007;**68**(6):818–25.
- 21 Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. *Journal of Clinical Epidemiology*. 1997;**50**(1):105–16.
- 22 Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records: description and validation. *Medical Care*. 1988;**26**(8):814–23.
- 23 Guenette L, Moisan J, Breton MC, Sirois C, Gregoire JP. Difficulty adhering to antidiabetic treatment: factors associated with persistence and compliance. *Diabetes & Metabolism*. 2013;**39**(3):250–7.
- 24 Gamble JM, McAlister FA, Johnson JA, Eurich DT. Restrictive drug coverage policies can induce substantial drug exposure misclassification in pharmacoepidemiologic studies. *Clinical Therapy*. 2012;**34**(6):1379–86, e3.
- 25 Franklin JM, Shrank WH, Pakes J, Sanfelix-Gimeno G, Matlin OS, Brennan TA, Choudhry NK. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. *Medical Care*. 2013;**51**(9):789–96.